Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-03
DOI
10.3389/fcell.2020.00425
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
- (2019) Jonathan L. Kaufman et al. Blood Cancer Journal
- Enantioselective synthesis and biological investigation of tetrahydro‐β‐carboline‐based HDAC6 inhibitors with improved solubility
- (2019) Elisabeth Grünstein et al. ARCHIV DER PHARMAZIE
- Posttranslational modifications and proteinopathies: how guardians of the proteome are defeated
- (2019) Heidi Olzscha BIOLOGICAL CHEMISTRY
- Modulation of autophagy: A phase II study of vorinostat (VOR) plus hydroxychloroquine (HCQ) vs regorafenib (RGF) in chemo-refractory metastatic colorectal cancer (mCRC).
- (2019) Sukeshi Patel Arora et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib for relapsed and refractory multiple myeloma
- (2019) K. Groen et al. Cancer Management and Research
- MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
- (2019) Fang-I Huang et al. Frontiers in Oncology
- HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy
- (2019) Valentina Condelli et al. Cells
- Epigenetic Alterations of Heat Shock Proteins (HSPs) in Cancer
- (2019) Hyun Seung Ban et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Biomarker definitions and their applications
- (2018) Robert M Califf EXPERIMENTAL BIOLOGY AND MEDICINE
- Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
- (2018) Andreas Sellmer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Systematic analysis of protein turnover in primary cells
- (2018) Toby Mathieson et al. Nature Communications
- Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
- (2018) Amit Singh et al. Nutrients
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
- (2018) Maria Cosenza et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Histone deacetylase 6 in cancer
- (2018) Ting Li et al. Journal of Hematology & Oncology
- Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
- (2018) Seung Yeob Hyun et al. Scientific Reports
- Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy
- (2018) Barbara Wegiel et al. Frontiers in Oncology
- The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death
- (2018) Maciej Kaliszczak et al. BRITISH JOURNAL OF CANCER
- A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer
- (2018) Toby A. Eyre et al. CANCER
- Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
- (2018) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Autophagy: An Essential Degradation Program for Cellular Homeostasis and Life
- (2018) Yoomi Chun et al. Cells
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53
- (2017) Maria Mrakovcic et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of the Tumor-Suppressor BECLIN 1 by Distinct Ubiquitination Cascades
- (2017) Fahd Boutouja et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
- (2017) S K Kumar et al. LEUKEMIA
- Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment
- (2017) Vahid Salimi et al. Lipids in Health and Disease
- The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
- (2017) Daniel N Cagney et al. NEURO-ONCOLOGY
- Protein Posttranslational Modifications: Roles in Aging and Age-Related Disease
- (2017) Ana L. Santos et al. Oxidative Medicine and Cellular Longevity
- Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function
- (2017) Naoe T. Nihira et al. Science Signaling
- HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness
- (2017) Janina Leyk et al. Cell Death & Disease
- Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines
- (2017) Xin Jin et al. Oncology Letters
- The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
- (2017) Laurence Booth et al. Oncotarget
- Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update
- (2017) Pere Llinàs-Arias et al. Open Biology
- Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
- (2017) Krysta Mila Coyle et al. Biomed Research International
- The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
- (2017) Tania Díaz et al. HAEMATOLOGICA
- The Glycolytic Switch in Tumors: How Many Players Are Involved?
- (2017) Li Yu et al. Journal of Cancer
- Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function
- (2017) Naoe T. Nihira et al. Science Signaling
- PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
- (2017) J. F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells
- (2016) Katrin Noack et al. ARCHIVES OF TOXICOLOGY
- Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112
- (2016) Beth E. Zucconi et al. BIOCHEMISTRY
- The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR
- (2016) L. Zhou et al. BLOOD
- Proteostasis impairment in ALS
- (2016) Céline Ruegsegger et al. BRAIN RESEARCH
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- Progress in the Development of non-BET Bromodomain Chemical Probes
- (2016) Natalie H. Theodoulou et al. ChemMedChem
- Bromodomain inhibitors and cancer therapy: From structures to applications
- (2016) Montserrat Pérez-Salvia et al. Epigenetics
- Trichostatin A, a histone deacetylase inhibitor suppresses NADPH Oxidase 4-Derived Redox Signalling and Angiogenesis
- (2016) Nora Y. Hakami et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- (2016) Mark L. McCleland et al. JOURNAL OF CLINICAL INVESTIGATION
- Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model
- (2016) Hui-Wen Chiu et al. Molecular Cancer
- Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer
- (2016) Sukeshi Patel et al. Oncotarget
- Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation
- (2016) Zhifei Wang et al. Scientific Reports
- Epigenetic polypharmacology: from combination therapy to multitargeted drugs
- (2016) Angel R. de Lera et al. Clinical Epigenetics
- Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
- (2016) Andrew R Conery et al. eLife
- Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
- (2015) Jianbin Zhang et al. Autophagy
- Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
- (2015) S. Picaud et al. CANCER RESEARCH
- Autophagy signal transduction by ATG proteins: from hierarchies to networks
- (2015) Sebastian Wesselborg et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Role of Histone Acetylation in Cell Cycle Regulation
- (2015) Miglena Koprinarova et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Epigenetic regulation in human melanoma: past and future
- (2015) Debina Sarkar et al. Epigenetics
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas
- (2015) Beata Holkova et al. LEUKEMIA & LYMPHOMA
- Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma
- (2015) D. Soodgupta et al. MOLECULAR CANCER THERAPEUTICS
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Protein neddylation: beyond cullin–RING ligases
- (2015) Radoslav I. Enchev et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Interplay between unfolded protein response and autophagy promotes tumor drug resistance
- (2015) MING-MING YAN et al. Oncology Letters
- Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- (2015) Gabor Borbely et al. Oncotarget
- Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma
- (2015) J. G. Berdeja et al. HAEMATOLOGICA
- Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial
- (2015) Daryl Tan et al. Lancet Haematology
- Hsp90, the Concertmaster: Tuning Transcription
- (2015) Nidhi Khurana et al. Frontiers in Oncology
- A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer
- (2015) Ya-Ting Yang et al. NEOPLASIA
- Activation of the Unfolded Protein Response Contributes toward the Antitumor Activity of Vorinostat
- (2015) Soumen Kahali et al. NEOPLASIA
- Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration
- (2014) Victoria Zismanov et al. ANTI-CANCER DRUGS
- Combined autophagy and HDAC inhibition
- (2014) Devalingam Mahalingam et al. Autophagy
- MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
- (2014) Y. Gu et al. BLOOD
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- The ubiquitin–proteasome system: opportunities for therapeutic intervention in solid tumors
- (2014) Daniel E Johnson ENDOCRINE-RELATED CANCER
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids
- (2014) Kunal Nepali et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate
- (2014) Sabita N. Saldanha et al. EXPERIMENTAL CELL RESEARCH
- HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes
- (2014) Monika Noack et al. GLIA
- The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
- (2014) Jun Long et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of HDAC6 Modifies Tau Inclusion Body Formation and Impairs Autophagic Clearance
- (2014) Janina Leyk et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
- (2014) Duncan A. Hay et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma
- (2014) A Moros et al. LEUKEMIA
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- The structure based design of dual HDAC/BET inhibitors as novel epigenetic probes
- (2014) Stephen J. Atkinson et al. MedChemComm
- Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
- (2014) E. Seto et al. Cold Spring Harbor Perspectives in Biology
- Molecular Chaperones, Cochaperones, and Ubiquitination/Deubiquitination System: Involvement in the Production of High Quality Spermatozoa
- (2014) Rosaria Meccariello et al. Biomed Research International
- Regulation of molecular chaperones through post-translational modifications: Decrypting the chaperone code
- (2013) Philippe Cloutier et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies
- (2013) Wei-Jan Huang et al. CANCER LETTERS
- A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
- (2013) M New et al. CELL DEATH AND DIFFERENTIATION
- The machinery of macroautophagy
- (2013) Yuchen Feng et al. CELL RESEARCH
- Chaperone-mediated autophagy: roles in disease and aging
- (2013) Ana Maria Cuervo et al. CELL RESEARCH
- Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
- (2013) Z. Cheng et al. CLINICAL CANCER RESEARCH
- Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
- (2013) Tianzhu Qiu et al. Future Oncology
- Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
- (2013) Tien Hoang et al. INVESTIGATIONAL NEW DRUGS
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
- (2013) Li Dong et al. Journal of Hematology & Oncology
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
- (2013) M V Stankov et al. LEUKEMIA
- Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
- (2013) U Platzbecker et al. LEUKEMIA
- A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study
- (2013) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Evading apoptosis in cancer
- (2013) Kaleigh Fernald et al. TRENDS IN CELL BIOLOGY
- Autophagy in tumor suppression and cancer therapy
- (2012) Che-Pei Kung et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- (2012) Akira Fukutomi et al. INVESTIGATIONAL NEW DRUGS
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer
- (2012) David R. Jones et al. Journal of Thoracic Oncology
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells
- (2012) Guang Yan et al. MOLECULAR CARCINOGENESIS
- HDAC inhibitor-based therapies: Can we interpret the code?
- (2012) Maria New et al. Molecular Oncology
- Epigenetic protein families: a new frontier for drug discovery
- (2012) Cheryl H. Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells
- (2012) I. Venza et al. Pigment Cell & Melanoma Research
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
- (2012) W. W. Lockwood et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Cell Metabolism: One Hallmark, Many Faces
- (2012) Jason R. Cantor et al. Cancer Discovery
- Autophagy as a target for cancer therapy: new developments
- (2012) Steffan Nawrocki et al. Cancer Management and Research
- Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)
- (2011) Amanda Cashen et al. ANNALS OF HEMATOLOGY
- Microautophagy: lesser-known self-eating
- (2011) Wen-wen Li et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Epigenetic Modifications
- (2011) Diane E. Handy et al. CIRCULATION
- Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
- (2011) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini
- (2011) Hui Ouyang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
- (2011) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- Autophagy as a target for anticancer therapy
- (2011) Filip Janku et al. Nature Reviews Clinical Oncology
- Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study
- (2011) B. B. Friday et al. NEURO-ONCOLOGY
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autophagy and apoptosis: what is the connection?
- (2011) Jacob M. Gump et al. TRENDS IN CELL BIOLOGY
- Cellular Strategies of Protein Quality Control
- (2011) B. Chen et al. Cold Spring Harbor Perspectives in Biology
- The acetylation of tau inhibits its function and promotes pathological tau aggregation
- (2011) Todd J. Cohen et al. Nature Communications
- Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma
- (2010) Yuan-Ling Liu et al. Autophagy
- The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
- (2010) Daniela Buglio et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
- (2010) Ruben Niesvizky et al. CANCER
- The Role of HDAC6 in Cancer
- (2010) Grace I. Aldana-Masangkay et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Autophagy: cellular and molecular mechanisms
- (2010) Danielle Glick et al. JOURNAL OF PATHOLOGY
- Heat Shock Protein 90 Inhibition in Lung Cancer
- (2010) Takeshi Shimamura et al. Journal of Thoracic Oncology
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- (2010) Eric Sanchez et al. LEUKEMIA RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
- (2010) O. Khan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Augmentation of the anticancer effects of proteasome inhibitors by combination with sodium butyrate in human colorectal cancer cells
- (2010) M.S.I. ABAZA Experimental and Therapeutic Medicine
- Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
- (2009) Susan Fotheringham et al. CANCER CELL
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Vorinostat enhances the antimyeloma effects of melphalan and bortezomib
- (2009) Richard A. Campbell et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- An operational definition of epigenetics
- (2009) S. L. Berger et al. GENES & DEVELOPMENT
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
- (2009) Jennifer S. Carew et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Targeting proteins for degradation
- (2009) Erin K Schrader et al. Nature Chemical Biology
- Converging concepts of protein folding in vitro and in vivo
- (2009) F Ulrich Hartl et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions
- (2009) C. Choudhary et al. SCIENCE
- The Effect of Proteasome Inhibition on p53 Degradation and Proliferation in Tonsil Epithelial Cells
- (2008) George F. Harris et al. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY
- HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2
- (2008) Annamaria Scognamiglio et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Role of Acetylation and Extracellular Location of Heat Shock Protein 90 in Tumor Cell Invasion
- (2008) Y. Yang et al. CANCER RESEARCH
- Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo
- (2008) W. Weichert et al. CLINICAL CANCER RESEARCH
- A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors
- (2008) N. L. Steele et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
- (2008) L. Ellis et al. CLINICAL CANCER RESEARCH
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- (2008) F. Braiteh et al. CLINICAL CANCER RESEARCH
- Heat Shock Protein 90 as a Drug Target: Some Like It Hot
- (2008) U. Banerji CLINICAL CANCER RESEARCH
- Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
- (2008) Sharmila Patel et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
- (2008) L Marquard et al. HISTOPATHOLOGY
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
- (2008) S. Vincent Rajkumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
- (2008) Marielle Dejligbjerg et al. Molecular Cancer
- Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells
- (2008) V. Duong et al. MOLECULAR CANCER RESEARCH
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
- (2008) M. Fournel et al. MOLECULAR CANCER THERAPEUTICS
- Diversity of degradation signals in the ubiquitin–proteasome system
- (2008) Tommer Ravid et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search